Is 2026 a Good Year to Start a Med Spa? Your Roadmap to a Sustainable Practice

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

If you are looking at the aesthetics industry right now and wondering if you missed the boat, the data from AmSpa tells a completely different story. Over the last few years, we have seen this industry explode. We have moved from a 15 billion dollar market to a space that is growing by over a […]

The post Is 2026 a Good Year to Start a Med Spa? Your Roadmap to a Sustainable Practice appeared first on Medical News Bulletin.

Vitrectomy finding its place in office-based surgical suite

Over the past decade, most ophthalmologists have become familiar with in-office cataract surgery, and more than 130 practices have begun offering the procedure.
Now, vitrectomy is also emerging as an option for office-based surgery (OBS).
Even before that idea stirred debate in the ophthalmology community, my practice became the first in the world to begin performing office-based vitrectomies at full scale. More than 3 years later, a dozen centers have adopted the strategy, including one in Ireland.
While conducting vitrectomy under oral sedation and a topical anesthetic is a disruptive idea, I

Upper lids matter for patient care, practice health

Despite a decade of growing attention to dry eye disease, millions of patients remain undiagnosed — whether symptomatic or asymptomatic — highlighting an opportunity to enhance comprehensive care, provide relief and support practice growth.
One persistent gap in comprehensive exams is the frequent omission of a simple diagnostic step: evaluating the upper eyelids. Historically, lower lid meibography was considered sufficient, and the practical challenges of upper lid eversion led many clinicians to forgo upper lid imaging altogether.
Emerging research shows that evaluating the upper

Chicago reports first rabies-positive dog in decades

A fully vaccinated dog tested positive for rabies last month in Chicago — the area’s first case in decades.
The dog was surrendered to a local rescue after exhibiting increased behavioral issues, including growling, snapping, barking and anxiety. Because of this behavior, the dog was euthanized on Dec. 18.
The dog had bitten a person on Dec. 11 and was tested for rabies after being euthanized, per state law. According to the Cook County Department of Animal and Rabies Control (ARC), it was the first rabies-positive dog in the county since before 1964 and the first in Illinois since 1994.
The

ASRM says polygenic embryo screening not ready for clinical use

The American Society for Reproductive Medicine published a report that concludes preimplantation genetic testing for polygenic disorders is not ready for clinical practice and should not yet be offered as a reproductive service.
According to a press release from the ASRM, it is not yet ready because of “the predictive uncertainties of the results and the substantial ethical considerations” that the practice raises.
“This analysis provides an ethics-based framework to guide clinicians, policymakers, patients and the public at large as they navigate the emergence of polygenic embryo screening,”

FDA fast tracks CTx001 for geographic atrophy

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary to age-related macular degeneration.
According to a press release from Complement Therapeutics, CTx001, an adeno-associated virus-based therapy, is designed to treat GA by delivering a truncated version of complement receptor 1, with the aim of yielding “long-term potent modulation of the classical and alternative pathways of the complement cascade.”
The FDA grants fast track designation to expedite the development and review of therapies that treat serious conditions

Updated congenital heart disease guidance unveiled

Professional cardiology societies have issued an updated guideline for the management of adult patients with congenital heart disease, which replaces its 2018 iteration.
The updated guideline addresses a variety of specific congenital heart diseases as well as strategies to mitigate barriers to lifetime continuous care, especially during the transition from childhood to adulthood.
The 2025 American College of Cardiology/American Heart Association Guideline for the Management of Adult Congenital Heart Disease was developed in collaboration with and endorsed by the Heart Rhythm Society,

Structured lifestyle intervention linked to improved blood regulation in brain, heart

Older adults who adhered to a structured lifestyle intervention saw greater improvement from blood flow and regulation mechanisms in both the brain and heart at 2 years than those who used a self-guided intervention, , data show.
“Multiple lines of evidence highlight the importance of vascular contributions to cognitive impairment and dementia,” Tina Brinkley, PhD, associate professor of gerontology and geriatrics, internal medicine at Wake Forest University School of Medicine, told Healio about the updated research from the POINTER study presented at CTAD.
“While most of this research is

Bimekizumab ‘preferred’ option when new psoriasis biologic needed

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at least one biologic, according to a real-world study.
Biologics have shown efficacy for the treatment of psoriasis, though patients may elect to discontinue certain biologics over time due to adverse events or eventual ineffectiveness, Christopher W. Schwarz, MD, PhD, of the department of dermatology and allergy at Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark, and colleagues wrote in JAMA Dermatology.
Drug survival, the measurement for how

Withdrawal from oral therapy tied to worsened hyperphagia in Prader-Willi syndrome

Children and adults with Prader-Willi syndrome who previously received once-daily diazoxide choline extended-release tablets and withdrew from the medication had worsening of hyperphagia at 16 weeks, according to study data.
In a double-blind, phase 3 randomized withdrawal period study published in The Journal of Clinical Endocrinology & Metabolism, people with Prader-Willi syndrome who previously received diazoxide choline extended-release tablets (Vykat XR, Soleno Therapeutics) in the randomized DESTINY-PWS phase 3 trial and its open-label extension were randomly assigned to continue the